[1] I. E. Scheffer, S. Berkovic, G. Capovilla, M. B. Connolly, J. French, L. Guilhoto et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017;58:512-21.
[2] T. Brenner, G. J. Sills, Y. Hart, S. Howell, P. Waters, M. J. Brodie et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia, 2013;54:1028-35.
[3] M. S. Ong, I. S. Kohane, T. Cai, M. P. Gorman, K. D. Mandl. Population-level evidence for an autoimmune etiology of epilepsy. JAMA neurology, 2014;71:569-74.
[4] D. Dubey, A. Alqallaf, R. Hays, M. Freeman, K. Chen, K. Ding et al. Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology. JAMA neurology, 2017;74:397-402.
[5] D. Dubey, J. Singh, J. W. Britton, S. J. Pittock, E. P. Flanagan, V. A. Lennon et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017;58:1181-9.
[6] M. Tecellioglu, O. Kamisli, S. Kamisli, F. E. Yucel, C. Ozcan. Neurological autoantibodies in drug-resistant epilepsy of unknown cause. Irish journal of medical science, 2018;187:1057-63.
[7] A. M. Quek, J. W. Britton, A. McKeon, E. So, V. A. Lennon, C. Shin et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Archives of neurology, 2012;69:582-93.
[8] D. Dubey, A. Sawhney, B. Greenberg, A. Lowden, W. Warnack, P. Khemani et al. The spectrum of autoimmune encephalopathies. Journal of neuroimmunology, 2015;287:93-7.
[9] A. M. L. Quek, O. O'Toole. Autoimmune Epilepsy: The Evolving Science of Neural Autoimmunity and Its Impact on Epilepsy Management. Seminars in neurology, 2018;38:290-302.
[10] D. Dubey, K. Blackburn, B. Greenberg, O. Stuve, S. Vernino. Diagnostic and therapeutic strategies for management of autoimmune encephalopathies. Expert review of neurotherapeutics, 2016;16:937-49.
[11] F. Ferracci, G. Bertiato, G. Moretto. Hashimoto's encephalopathy: epidemiologic data and pathogenetic considerations. Journal of the neurological sciences, 2004;217:165-8.
[12] P. R. Castillo, E. Mignot, B. K. Woodruff, B. F. Boeve. Undetectable CSF hypocretin-1 in "Hashimoto's encephalopathy" associated with coma. Neurology, 2004;62:1909.
[13] S. J. Pittock, H. Yoshikawa, J. E. Ahlskog, S. H. Tisch, E. E. Benarroch, T. J. Kryzer et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clinic proceedings, 2006;81:1207-14.
[14] M. Toledano, J. W. Britton, A. McKeon, C. Shin, V. A. Lennon, A. M. Quek et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology, 2014;82:1578-86.
[15] D. Dubey, Z. Farzal, R. Hays, L. S. Brown, S. Vernino. Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis. Therapeutic advances in neurological disorders, 2016;9:369-77.
[16] D. Dubey, N. Samudra, P. Gupta, M. Agostini, K. Ding, P. C. Van Ness et al. Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy. Seizure : the journal of the British Epilepsy Association, 2015;29:143-7.
[17] A. Vincent, S. R. Irani, B. Lang. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Current opinion in neurology, 2010;23:144-50.
[18] Z. W. Xu CL, Li JM, Wang JW, Wang SH, Wang XD, et al. Anti-N-methyl-D-aspartate receptor encephalitis: A case report (in Chinese). Chin J Neurol, 2010;43:781-3.
[19] H. Z. Guan, H. T. Ren, L. Y. Cui. Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology. Chinese medical journal, 2016;129:1122-7.
[20] C. Zeng, M. Wang, C. Zhang, B. Xiao, W. Liu. [Association between admission diagnosis and immunotherapy outcome in patients with autoimmune epilepsy]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2019;44:885-91.
[21] R. S. Fisher, C. Acevedo, A. Arzimanoglou, A. Bogacz, J. H. Cross, C. E. Elger et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia, 2014;55:475-82.
[22] D. Dubey, N. Kothapalli, A. McKeon, E. P. Flanagan, V. A. Lennon, C. J. Klein et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of neuroimmunology, 2018;323:62-72.
[23] F. Graus, M. J. Titulaer, R. Balu, S. Benseler, C. G. Bien, T. Cellucci et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet neurology, 2016;15:391-404.
[24] D. Dubey, M. Toledano, A. McKeon. Clinical presentation of autoimmune and viral encephalitides. Curr Opin Crit Care, 2018;24:80-90.
[25] L. Li, L. Sun, R. Du, Y. Zheng, F. Dai, Q. Ma et al. Application of the 2016 diagnostic approach for autoimmune encephalitis from Lancet Neurology to Chinese patients. BMC Neurol, 2017;17:195.
[26] Y. Wang, W. Zhang, J. Yin, Q. Lu, F. Yin, F. He et al. Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China: Clinical features, treatment, influencing factors, and outcomes. Journal of neuroimmunology, 2017;312:59-65.
[27] T. J. Kim, S. T. Lee, J. W. Shin, J. Moon, J. A. Lim, J. I. Byun et al. Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. Journal of neuroimmunology, 2014;270:45-50.
[28] A. Baumgartner, S. Rauer, T. Hottenrott, F. Leypoldt, F. Ufer, H. Hegen et al. Admission diagnoses of patients later diagnosed with autoimmune encephalitis. Journal of neurology, 2019;266:124-32.
[29] A. Greco, M. I. Rizzo, A. De Virgilio, M. Conte, A. Gallo, G. Attanasio et al. Autoimmune epilepsy. Autoimmunity reviews, 2016;15:221-5.
[30] L. Zuliani, F. Graus, B. Giometto, C. Bien, A. Vincent. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. Journal of neurology, neurosurgery, and psychiatry, 2012;83:638-45.